Found 41 clinical trials
Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers
The aim of this trial is an evaluation of the effectiveness of intermittent fasting as a supplementary therapy in patients with breast cancer and ovarian cancer in respect to quality of life, reduction of side effects and possible reduction in tumor progression.
- 21 views
- 23 Jan, 2021
- 8 locations
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate Safety and tolerability of MASCT-I in patients with advanced solid tumors, either alone or in combination with chemical drugs or in combination with PD1 antibody.
- 81 views
- 25 Jan, 2021
- 9 locations
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Our recent trials combining local radiotherapy with intratumoral administration of TLR agonists - referred to as 'in situ vaccination' - for patients with low-grade lymphoma demonstrated safety, induction of anti-tumor CD8 T cell responses and partial and complete remissions of patients' non-irradiated sites of disease with complete remissions lasting from …
- 9 views
- 26 Jan, 2021
- 1 location
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Background One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells. Objective To see if giving anti-CD22 …
- 31 views
- 01 Jul, 2021
- 1 location
TPIV100 and Sargramostim for the Treatment of HER2 Positive Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has remained after chemotherapy and surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is …
- 0 views
- 18 Apr, 2021
- 3 locations
Swiss Severe Asthma Register
Asthma is one of the most common chronic diseases. Asthma is characterized by chronic airway inflammation and associated with airway hyperresponsiveness and reversible airflow obstruction. The variability of airway obstruction is triggered by different factors that lead to a variety of different asthma phenotypes and subtypes. The various classification options …
- 16 views
- 26 Jan, 2021
- 20 locations
Observational Study of Characteristics Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled
- 2990 views
- 23 Jul, 2021
- 145 locations
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
- 0 views
- 28 Jan, 2021
- 1 location
Clonal Evolution in Follicular Lymphoma
Background Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future …
- 77 views
- 07 May, 2021
- 1 location
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
Patients with severe eosinophilic asthma will be placed on biologics if they continue to be uncontrolled despite maximized inhalation therapy or if they are only controlled under oral corticosteroids. Among biologics, 80% of patients respond to treatment and improve clinically, but approximately 20% are non-responders and up to date no …
- 0 views
- 25 Jan, 2021
- 1 location